David Lederer, M.D., M.S.

Associate Professor of Medicine and Epidemiology (In Pediatrics)
Co-director, Interstitial Lung Disease Program and NYP PFF Care Center Pulmonary Director, Pulmonary & Intensive Care Translational Outcomes Research (PICTOR) Group


Dr. Lederer is an attending physician at New York Presbyterian Hospital/Columbia where he cares for patients with interstitial lung diseases, including idiopathic pulmonary fibrosis. He is the principal investigator of two NHLBI-funded studies: the MESA Lung Fibrosis Study and the Lung Transplant Body Composition Study. He is a Deputy Editor of the Annals of the American Thoracic Society and sits on the Editorial board of the American Journal of Respiratory and Critical Care Medicine and on the Statistical Editorial Board for Thorax. Dr. Lederer is a Senior Medical Advisory for the Pulmonary Fibrosis Foundation and a standing member of the IRAP study section at the Center for Scientific Review at NIH. He is a member of the Technical Advisory Committee for the Scientific Registry of Transplant Recipients and a member of the Research and Scientific Advisory Board of the American Lung Association. He blogs at www.pfdoc.org for patients with pulmonary fibrosis.

Dr. Lederer's research focuses on two related areas (1) enhancing the understanding of the causes of lung fibrosis in humans, and (2) improving outcomes after lung transplantation by investigating and improving candidacy for the procedure. His leads research efforts in the following areas:

  • Causes of interstitial lung disease
  • Frailty and obesity in lung transplantation
  • Novel therapies for idiopathic pulmonary fibrosis
  • Disparities in deceased donor organ allocation
  • Obesity, sleep apnea, and lung injury

Education and Training

B.S. in Biology, Adelphi University, Garden City, NY, 1995
M.S., Biostatistics, Columbia University Mailman School of Public Health, 2007
Medical School:
SUNY Downstate College of Medicine, Brooklyn, NY, 1999
Department of Medicine, Columbia Presbyterian Medical Center, NY, NY, 1999-2000
Department of Medicine, Columbia Presbyterian Medical Center, 2000-2002
Chief Residency:
Department of Medicine, Columbia Presbyterian Medical Center, 2002-2003
Pulmonary and Critical Care Fellow, Columbia Presbyterian Medical, Center, 2003-2005
Research Fellow, Columbia Presbyterian Medical Center, New York T32 HL072739; Mentor: Neil Schluger, M.D, 2005-2006.

Honors and Awards

  • 2014 Harold and Golden Lamport Award for Excellence in Clinical Science Research
  • 2014 Ewig Clinical Scholar (CUMC Teaching Award)
  • 2013-2015 New York Super Doctors
  • 2012-2015 Top Doctor: New York Metro Area, US News & World Report/Castle Connolly
  • 2008-2011 Herbert and Florence Irving Scholar
  • 2008-2011 Robert Wood Johnson Physician Faculty Scholar

Other Experience and Professional Membership












  • 2015-2019 NIH/CSR: Standing member, IRAP study section, Center for Scientific Review
  • 2015-2017 Chair, Planning Committee, Clinical Problems Assembly, American Thoracic Society
  • 2015 Member, SRTR Technical Advisory Committee (www.srtr.org/Stac)
  • 02/2015 NIH/NHLBI MPOR-MA study section: K23, K24, K25 Career Development Award
  • 11/2014 VA-ORD RR&D Small Projects in Rehabilitation Research (SPiRE) (I21), RFA: RX-14-009
  • 10/2014 NIH/NHLBI ZHL1 CSR-X (O1) 1: K23, K24, K25 Career Development Award
  • 09/2014 NIH/CSR: IRAP ad hoc reviewer (R01/R03)
  • 07/2014 NIH/CSR ZRG1 RPHB-S (02) M: Member Conflict: Behavioral Interventions, Obesity, and Chronic Pain (R01)
  • 06/2014 NIH/NHLBI ZHL1 CSR-X (O1) 1: K23, K24, K25 Career Development Award
  • 2014 Senior Medical Advisor, Pulmonary Fibrosis Foundation, Education & Awareness
  • 2014 Member, Research and Scientific Advisory Board, American Lung Association
  • 03/2014 NIH/NHLBI ZRG1 PSE-Q (56): PAR-13-009: Secondary Dataset Analyses in Heart, Lung, and Blood Diseases and Sleep (R21), Mail



  • 11/2013 National Health Service (NHS) National Institute for Health Research (NIHR) Clinician Scientist Programme review committee (K equivalent)

    Mail Reviewer:
  • 11/2013 National Health Service (NHS) Scotland, Chief Scientist Office: Experimental and Translational Medicine Research Committee, Mail reviewer
  • 06/2013 NIH/CSR: IRAP ad hoc reviewer (R01/R03)
  • 02/2013 NIH/NHLBI SEP: Phase II Clinical Trials of Novel Therapies for Lung Diseases (UM1)
  • 11/2012 NIH/NHLBI ZHL1 CSR-P (F1): Maximizing the scientific value of the NHLBI biologic specimen repository: Scientific opportunities (R21) (UM1)
  • 02/2012 NIH/NHLBI ZHL1 CSR-F (M1): Mentoring programs to promote diversity in health research (K01/R25)
  • 2012-2013 Member, NHLBI Workshop, Primary Prevention of Chronic Lung Diseases
  • 2011-2014 American Lung Association Research Training Fellowship Study Section

  • 2015 Statistical Editorial Board, Thorax
  • 2013 Editorial Board, American Journal of Respiratory and Critical Care Medicine
  • 2012 Deputy Editor, Annals of the American Thoracic Society


For appointments: 

Columbia ILD and PF Care Center
Columbia University Medical Center
622 W 168th Street, VC-3, Room 365
New York, NY 10032
Admin Assistant (Susanne): 212-305-8203
Fax: 212-305-8426


  • Pulmonary Disease Medicine
  • Lung Transplantation

Clinical Expertise

  • Interstitial lung disease
  • Idiopathic pulmonary fibrosis
  • Lung transplantation

Clinical Centers

Board Certifications

  • Internal Medicine Diplomate, 2002
  • Pulmonary Disease Diplomate, 2005
  • Critical Care Medicine Diplomate, 2006


Contact Information: 

Pulmonary & Intensive Care Translational Outcomes Research (PICTOR) Group
Lederer Laboratory
Department of Medicine
Columbia University Medical Center
622 W 168th Street, PH-14, Room 404
New York, NY 10032
Project Coordinator (Nisha): 212-305-7720
Clinical Trials Coordinator (Tatiana): 212-342-4167
Grants Administrator (Cicely): 212-305-7074

Research Interests

  • Subclinical interstitial lung disease
  • Body composition and lung transplantation
  • Disparities in access to subspecialty pulmonary services and lung transplantation
  • Obstructive sleep apnea and alveolar injury


  • R01 HL103676 (Lederer) 04/15/2011 – 04/14/2015
    Subclinical Interstitial Lung Disease in MESA
    The Aims of this project are to validate high attenuation areas (HAA) on CT lung imaging as a marker of subclinical interstitial lung disease and perform genome wide association and linkage studies of HAA.
    Role: PI
  • R01 HL081619 (Christie) 02/15/2007 – 01/31/2013
    Genetics of Primary Graft Dysfunction
    This study aims to identify genetic predictors of predict primary graft failure after lung transplant.
    Role: Co-Investigator (Columbia site PI)
  • R01 HL087115 (Christie) 08/15/2007 – 07/31/2012
    Clinical Risk Factors for Primary Graft Dysfunction
    This is a study to identify clinical predictors of primary graft failure after lung transplantation.
    Role: Co-Investigator (Columbia site PI)
  • R25 HL105401 (Begg) 09/25/2010 – 07/31/2014
    FIRST in CER (Facilitating Independence in Research through the Summer Training in Comparative Effectiveness Research) Diversity Program
    This program provides summer training and mentoring in skills essential to conducting comparative effectiveness research (CER), enhancing the career development of faculty and scientists from diverse backgrounds in basic and applied sciences relevant to heart, lung, blood, and sleep disorders.
    Role: Collaborator
  • R25 HL096260 (Begg) 05/15/2009 – 04/30/2014
    BEST-DP: Biostatistics Enrichment Summer Training Diversity Program
    This program provides research opportunities in biostatistics, cardiovascular disease, and pulmonary disease for individuals who are under- represented in biomedical research (those from disadvantaged backgrounds, racial and ethnic minorities, and individuals with disabilities), and who will contribute to a more diverse research workforce in the future.
    Role: Collaborator
  • BI 1199.32 07/01/2011– 12/31/2015
    A 52 week, double-blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150mg twice daily, on annual FVC decline in patients with IPF
    This is a multicenter clinical trial of BIBF 1120 to treat IPF.
    Role: Columbia site PI
  • Irving Pilot Award 07/01/2012– 06/30/2013
    Irving Institute for Clinical and Translational Research (Columbia CTSA)
    Obesity, Lung Transplantation, and Lung Injury
    The major goal of this pilot study is to examine the use of quantitative CT imaging to ascertain adipose tissue distribution in lung transplant candidates.
    Role: PI
  • U01 HL105371 (Choi) 03/01/2012– 06/30/2014
    Phase II Study of Inhaled Carbon Monoxide for the Treatment of IPF
    The purpose of this study is test the safety and efficacy of inhaled carbon monoxide in IPF.
    Role: Co-investigator (Columbia site PI)
  • R01 HL114468 (Hancock) 05/15/2012 – 03/31/2016
    Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients
    The Aims of this project are to examine role of Treg cells in primary graft dysfunction after lung transplantation.
    Role: Co-investigator (Columbia site PI)

Selected Publications

  1. Baldwin, MR, Arcasoy SM, Shah A, Sze J, Sonett JR, Lederer DJ. Hypoalbuminemia and early mortality after lung transplantation: a cohort study. Am J Transplant 2012;12(5):1256-67.
  2. Hook JL, Arcasoy SM, Zemmel D, Bartels M, Kawut SM, Lederer DJ. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J 2012;39(2):359-65.
  3. Lederer DJ, Kawut S, Wikersham N, Winterbottom C, Bhorade S, Palmer S, Lee J, Diamond J, Wille K, Weinacker A, Lama V, Crespo M, Orens J, Sonett J, Arcasoy S, Ware L, Christie J. Obesity and primary graft dysfunction after lung transplantation: the LTOG Obesity Study. Am J Respir Crit Care Med 2011;184:1055-61.
  4. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842-7.
  5. Lederer DJ, Wilt JS, D’Ovidio F, Bacchetta M, Shah L, Ravichandran S, Lenoir J, Klein B, Sonett JR, Arcasoy SM. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med 2009;180(9):887-95.
  6. Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJR, Austin JHM, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: The MESA-Lung Study. Am J Respir Crit Care Med 2009;180(5):407-14.
  7. Lederer DJ¸ Jelic S, Basner RC, Ishizaka A, Bhattacharya J. Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnea. Eur Respir J 2009;33(4):793-6.
  8. Lederer DJ, Benn EKT, Barr RG, Wilt JS, Reilly G, Sonett JR, Arcasoy SM, Kawut SM. Racial differences in waiting list outcomes in COPD. Am J Respir Crit Care Med 2008;177(4):450-454.
  9. Lederer DJ, Arcasoy SM, Barr RG, Wilt JS, Bagiella E, D'Ovidio F, Sonett JR, Kawut SM. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant 2006;6(10):2436-42.
  10. Lederer DJ, Caplan-Shaw CE, O’Shea MK, Wilt JS, Basner RG, Bartels MN, Sonett JR, Arcasoy SM, Kawut SM. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 2006;6:398-403.

View Dr. Lederer's full list of publications from PubMed